Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...

Boxed safety warning The label for Camzyos does however include a boxed warning for worsening heart failure, which is tied to the mechanism of the drug in reducing LVEF and the workload on the ...

Shares of Bristol Myers BMY have lost 20.7% in the past three months compared with the industry ’s decline of 9.6%. The stock ...

The rapid take-up puts Camzyos on course to achieve blockbuster ... while BMS has said it believes the drug could reach $4 billion if its label is extended to include non-obstructive HCM, for ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Camzyos benefited from a favorable label update in the U.S. and approval ... including tariffs and drug pricing reforms, and is leveraging its U.S.-based manufacturing and flexible supply chain ...

In May, the FDA granted 5 significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

The FDA is delaying implementation of a rule that would require food companies to print nutritional information on the front labels of their products. The proposed rule was developed by President ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Camzyos (mavacamten) is a prescription drug that’s used in certain adults with obstructive hypertrophic cardiomyopathy (HCM). Camzyos comes as an oral capsule. Specifically, Camzyos is used in ...